| Question 1: Heavy element-based nanoparticles (such as gold nanoparticles) provide inherent contrast/therapeutic benefits for which theranostic modality pair: |
| Reference: | Mieszawska, A. J.; Mulder, W. J. M.; Fayad, Z. A.; Cormode, D. P., Multifunctional gold nanoparticles for diagnosis and therapy of disease. Mol. Pharmaceutics 2013, 10 (4), 831- 847. |
| Choice A: | MRI and gene delivery |
| Choice B: | CT and radiotherapy |
| Choice C: | Ultrasound and photodynamic therapy |
| Question 2: Theranostics can provide which of the following types of information: |
| Reference: | Feng, Y.; Panwar, N.; Tng, D. J. H.; Tjin, S. C.; Wang, K.; Yong, K.-T., The application of mesoporous silica nanoparticle family in cancer theranostics. Coord. Chem. Rev. 2016, 319, 86-109. |
| Choice A: | Drug efficacy |
| Choice B: | Drug accumulation |
| Choice C: | Drug delivery to target cell type |
| Question 3: At what temperature does photothermal ablation occurs instantaneously? |
| Reference: | Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys. 1984;10:787-800 |
| Choice A: | < 37 °C |
| Choice B: | 38-41 °C |
| Choice C: | 42-46 °C |
| Choice D: | >54 °C |
| Question 4: Which of the following ligands have been used as targeting agents for cancer: |
| Reference: | Melancon MP, Zhou M, Li C. Cancer Theranostics with Near-Infrared Light- Activatable Multimodal Nanoparticles. Acc Chem Res 44(10):947-956, 10/2011. e-Pub 8/2011. PMCID: PMC3196765. |
| Choice A: | peptides |
| Choice B: | aptamers |
| Choice C: | antibodies |
| Choice D: | all of the above |
| Question 5: Which characteristic of monoclonal antibodies makes zirconium-89 a particularly appropriate partner for the construction of radioimmunoconjugates? |
| Reference: | Deri, M. A., Zeglis, B. M., Francesconi, L. C., Lewis, J. S. PET Imaging with 89Zr:
From Radiochemistry to the Clinic. Nucl. Med. Bio. 40, 3 (2013) |
| Choice A: | The difficulty associated with their bioconjugation |
| Choice B: | The instability in vivo |
| Choice C: | Their multi-day serum half-life |
| Choice D: | Their resistance to radiolysis |
| Question 6: In the absence of a chelator, what is the destination of [89Zr]Zr4+ in the body? |
| Reference: | Abou, D.S., Ku, T., Smith-Jones, P.M. In Vivo Biodistribution and Accumulation of 89Zr in Mice. Nucl. Med. Biol. 38(5), 675 (2011) |
| Choice A: | The brain |
| Choice B: | The bones |
| Choice C: | The liver |
| Choice D: | The kidneys |
